Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter "Elix"), an AI drug discovery company with the mission of "Rethinking Drug Discovery", today announced that it has entered into a drug discovery ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

What was once an entry point into makeup has taken center stage in the cosmetics aisle and even become a coveted accessory. Ahead, the juicy lip formulas—from glosses to oils to tinted balms—to carry ...

PRISM BioLab & Elix join forces to speed up AI-driven drug discovery for protein-protein interaction targets: Tokyo, Japan Tuesday, April 15, 2025, 16:00 Hrs [IST] PRISM BioLab, C ...

McFarland placed the Idaho land for sale, the crown jewel of his operations, in December for $27 million. The property, which ...

Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in people taking the potent weight loss drugs.

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive up to $493 million in upfront, development, regulatory ...

PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced ...

Industrial farming practices often deplete the soil of important nutrients and minerals, leaving farmers to rely on ...

The craze for protein began before the introduction of GLP-1 drugs being made available to U.S. consumers to assist in weight ...